Pulmonary Embolism And Anticoagulation Follow-Up - USMLE Step 3

1. A 61-year-old man is discharged 3 days ago after PE provoked by trauma and immobilization. He is on warfarin with enoxaparin bridge; target INR 2.0–3.0. He returns with mild hemoptysis and extensive ecchymoses on arms. Vitals stable. Labs: INR 4.2, Hgb 13.0 g/dL, platelets 220k, creatinine 1.6 mg/dL (eGFR 44 mL/min/1.73 m²). He has continued enoxaparin injections because he misunderstood instructions. Based on the scenario, what adjustment, if any, should be made to the patient's anticoagulation therapy?
   Answer: Stop enoxaparin immediately and hold warfarin temporarily with prompt INR recheck This question tests the understanding of pulmonary embolism management and anticoagulation follow-up in a clinical context relevant to USMLE Step 3. The principle focus is on applying clinical guidelines for anticoagulation management and recognizing complications arising from therapy. In this scenario, factors such as the patient's INR of 4.2, mild hemoptysis, ecchymoses, and continued enoxaparin bridge are critical for decision-making. The correct answer addresses these factors by suggesting stopping enoxaparin immediately and holding warfarin temporarily with INR recheck, demonstrating the application of clinical guidelines for managing overanticoagulation from prolonged bridging. A common distractor might suggest continuing both agents, which fails to consider the bleeding risk from dual therapy. To prepare for similar questions, students should focus on understanding anticoagulation management guidelines, recognize symptoms indicative of complications, and practice applying this knowledge to case scenarios.
2. A 50-year-old man with a first unprovoked pulmonary embolism is completing a 6-month course of anticoagulation with apixaban. He has an intermediate bleeding risk and is uncertain about continuing therapy indefinitely. What is the most appropriate use of D-dimer testing to assist in shared decision-making?
   Answer: A negative D-dimer measured one month after stopping apixaban suggests a lower risk of recurrence. In patients with a first unprovoked VTE who are stopping anticoagulation, a D-dimer level can help stratify the risk of recurrence. The test should be performed approximately one month after discontinuing therapy. A negative result is associated with a lower risk of recurrence, and this information can support a decision to remain off anticoagulation. A positive result suggests a higher risk, favoring resumption of therapy. Measuring D-dimer while on anticoagulation is not useful as the drug suppresses D-dimer formation.
3. A 56-year-old man with a history of an unprovoked PE two years ago, for which he completed a 6-month course of apixaban, presents to the emergency department with acute-onset pleuritic chest pain. His vital signs are stable and his oxygen saturation is 98% on room air. He has no signs of a DVT. How does his prior PE history influence the immediate diagnostic workup?
   Answer: His history makes the Pulmonary Embolism Rule-out Criteria (PERC) inapplicable. A prior history of DVT or PE is one of the eight criteria in the PERC rule. If any criterion is present, the rule is not met, and PE cannot be ruled out on clinical grounds alone. This patient's history automatically places him in a higher pre-test probability category where further diagnostic testing, such as a D-dimer assay or imaging, is warranted. Stating that he meets PERC criteria is incorrect. His history is a major risk factor for recurrence and is highly relevant. The choice between V/Q and CTA depends on other factors and is not mandated by the history alone.
4. A patient with active cancer and PE has recurrent PE while adherent to enoxaparin. Best next step?
   Answer: Increase enoxaparin by 25% Recurrent PE on therapeutic enoxaparin in active cancer means the current dose is insufficient; guidelines recommend increasing LMWH by 25% rather than changing agents. Warfarin is the tempting choice because it is an anticoagulant, but cancer-associated VTE responds less reliably to warfarin, and IVC filter alone or aspirin doesn't treat the underlying thrombosis.
5. A 63-year-old man with recurrent PE is on long-term warfarin, target INR 2.0–3.0, monitored monthly. He presents with 2 days of black tarry stools and dizziness. Risk factors include obesity and prior unprovoked VTE; no cancer. Vitals: BP 96/58, HR 118, SpO2 99% RA. Exam shows pallor. Labs: INR 2.7, Hgb 6.9 g/dL, platelets 240k, creatinine 1.0 mg/dL (eGFR 80 mL/min/1.73 m²). What is the most appropriate next step in management for this patient?
   Answer: Hold warfarin, resuscitate, and treat suspected major gastrointestinal bleeding urgently This question tests the understanding of pulmonary embolism management and anticoagulation follow-up in a clinical context relevant to USMLE Step 3. The principle focus is on applying clinical guidelines for anticoagulation management and recognizing complications arising from therapy. In this scenario, factors such as the patient's black tarry stools, dizziness, hypotension, tachycardia, and significant hemoglobin drop despite therapeutic INR are critical for decision-making. The correct answer addresses these factors by suggesting holding warfarin, resuscitating, and urgently treating major gastrointestinal bleeding, demonstrating the application of clinical guidelines for major bleeding events. A common distractor might suggest continuing warfarin, which fails to consider the life-threatening nature of the bleed. To prepare for similar questions, students should focus on understanding anticoagulation management guidelines, recognize symptoms indicative of complications, and practice applying this knowledge to case scenarios.
6. After 6 months of apixaban for PE, her breast cancer still requires chemotherapy. Best plan?
   Answer: Continue full-dose apixaban Active cancer plus chemotherapy keeps the patient at high risk for recurrent venous thromboembolism, so anticoagulation should continue beyond 6 months at full treatment dose. Apixaban is a preferred DOAC for cancer-associated thrombosis. The tempting error is stopping at 6 months, which applies to provoked PE without ongoing cancer; enoxaparin 40 mg is only prophylaxis, not treatment.
7. Patient takes warfarin after unprovoked PE 9 months ago. Elective surgery in 5 days. Plan?
   Answer: Stop warfarin now; no bridge Warfarin must be held 5 days before surgery to normalize the INR. A VTE 3 to 12 months earlier puts this patient in the MODERATE perioperative risk tier, not the low tier, which requires more than 12 months. Even so, bridging is not indicated: trial evidence shows LMWH bridging adds bleeding risk without reducing thromboembolism outside the highest-risk groups. The tempting error is to bridge anyway, which is reserved for very recent VTE, severe thrombophilia, or a mechanical valve.
8. A 44-year-old postpartum woman (3 weeks after delivery) was treated for PE diagnosed 10 days ago. Risk factors include recent pregnancy, prolonged bed rest, and obesity; no prior VTE. She is on warfarin with target INR 2.0–3.0 and is breastfeeding; INR checks occur every 3 days. She now reports mild hemoptysis and heavy vaginal bleeding soaking pads hourly. Vitals: BP 98/60, HR 112, SpO2 97% RA. Labs: INR 3.9, Hgb 7.9 g/dL, platelets 250k, creatinine 0.7 mg/dL. What is the most appropriate next step in management for this patient?
   Answer: Hold warfarin, give reversal as needed, and urgently evaluate postpartum hemorrhage This question tests the understanding of pulmonary embolism management and anticoagulation follow-up in a clinical context relevant to USMLE Step 3. The principle focus is on applying clinical guidelines for anticoagulation management and recognizing complications arising from therapy. In this scenario, factors such as the patient's INR of 3.9, heavy vaginal bleeding, hemoglobin drop, hypotension, and tachycardia are critical for decision-making. The correct answer addresses these factors by suggesting holding warfarin, giving reversal as needed, and urgently evaluating postpartum hemorrhage, demonstrating the application of clinical guidelines for major bleeding in the postpartum period. A common distractor might suggest continuing warfarin and reassuring the patient, which fails to consider the severity of bleeding and hemodynamic instability. To prepare for similar questions, students should focus on understanding anticoagulation management guidelines, recognize symptoms indicative of complications, and practice applying this knowledge to case scenarios.
9. A 68-year-old man on long-term rivaroxaban 20 mg daily for recurrent unprovoked PEs is scheduled for a screening colonoscopy with likely polypectomy. This is considered a high-bleeding-risk procedure. What is the most appropriate peri-procedural plan for his anticoagulation?
   Answer: Stop rivaroxaban 2 days (48 hours) before the procedure and resume after hemostasis is secure. For patients on a DOAC like rivaroxaban undergoing a high-bleeding-risk procedure, the medication should be temporarily held. Due to its short half-life, holding it for 48 hours (i.e., skipping 2 doses) is generally sufficient. Bridging with LMWH is not recommended for patients on DOACs as it increases bleeding risk without a proven benefit in VTE prevention. Continuing rivaroxaban would pose an unacceptably high risk of post-polypectomy bleeding. Switching to aspirin is not an appropriate VTE prevention strategy.
10. A 68-year-old woman on rivaroxaban for unprovoked PE (18 months ago) presents for routine follow-up. Risk factors include obesity and prior DVT; no malignancy. She reports progressive fatigue and exertional dyspnea but no chest pain. She denies overt bleeding. Vitals: HR 92, BP 122/74, SpO2 97% RA. Labs: Hgb 8.9 g/dL (baseline 12.9), MCV 72 fL, platelets 310k, creatinine 1.1 mg/dL (eGFR 60 mL/min/1.73 m²), INR 1.2. Stool guaiac is positive. What is the most appropriate next step in management for this patient?
    Answer: Evaluate for occult gastrointestinal bleeding while reassessing anticoagulation risks and benefits This question tests the understanding of pulmonary embolism management and anticoagulation follow-up in a clinical context relevant to USMLE Step 3. The principle focus is on applying clinical guidelines for anticoagulation management and recognizing complications arising from therapy. In this scenario, factors such as the patient's progressive fatigue, exertional dyspnea, anemia, microcytosis, and positive stool guaiac are critical for decision-making. The correct answer addresses these factors by suggesting evaluation for occult gastrointestinal bleeding while reassessing anticoagulation risks and benefits, demonstrating the application of clinical guidelines for managing chronic bleeding on DOACs. A common distractor might suggest continuing rivaroxaban without investigation, which fails to consider the need to identify and address the bleeding source. To prepare for similar questions, students should focus on understanding anticoagulation management guidelines, recognize symptoms indicative of complications, and practice applying this knowledge to case scenarios.
11. A 28-year-old competitive runner was diagnosed with a PE two weeks ago. He was started on apixaban and his shortness of breath has resolved. He is hemodynamically stable and eager to resume training. What is the most appropriate advice regarding physical activity?
    Answer: He can begin a gradual return to his training regimen as tolerated, avoiding contact sports. Early ambulation and a gradual return to physical activity are encouraged after an acute PE as soon as the patient is hemodynamically stable and symptoms allow. Prolonged immobility is a risk factor for VTE. The main restriction while on anticoagulation is to avoid activities with a high risk of traumatic injury and bleeding (e.g., contact sports). Therefore, a gradual, sensible return to running is appropriate. Bed rest is contraindicated. An immediate return to full-intensity training without a gradual ramp-up is not advisable.
12. A 42-year-old woman with a known diagnosis of high-risk antiphospholipid syndrome (positive for all three antibody types) is hospitalized with an acute pulmonary embolism. She has a prior history of a cerebral ischemic attack. What is the most appropriate anticoagulant for long-term secondary prevention in this patient?
    Answer: Warfarin with a target INR of 2.0-3.0. For patients with antiphospholipid syndrome (APS), particularly high-risk patients (triple-positive or with a history of arterial thrombosis), warfarin remains the standard of care for treating VTE. Clinical trials have suggested that direct oral anticoagulants (DOACs) may be associated with a higher rate of recurrent thrombosis, especially arterial events, compared to warfarin in this specific population. Therefore, DOACs like apixaban and rivaroxaban should be avoided. Aspirin monotherapy is inadequate for VTE treatment.
13. A 38-year-old woman is seen for a 3-month follow-up visit after being diagnosed with a PE provoked by a 14-hour flight. She has been taking apixaban, and her symptoms have completely resolved. She is concerned and asks if she needs another CT scan to see if the clot has dissolved. What is the most appropriate response?
    Answer: Routine follow-up imaging is not recommended as it rarely alters the management plan. Routine imaging (either CT or V/Q scan) to assess for clot resolution after a course of treatment for acute PE is not recommended in asymptomatic patients. The findings do not reliably predict recurrence risk and do not alter the planned duration of therapy, which is based on whether the PE was provoked or unprovoked and the patient's bleeding risk. Such imaging would lead to unnecessary radiation exposure, cost, and risk of contrast-induced nephropathy. Residual thrombus is a common finding and does not automatically necessitate lifelong therapy, especially for a provoked PE.
14. A pregnant patient on LMWH for acute PE asks how her dose should be monitored. Best response?
    Answer: Anti-Xa levels guide dose Pregnancy changes LMWH clearance and volume of distribution, so anti-Xa levels are used to monitor and adjust the dose. Checking PT/INR is tempting, but that tests warfarin, not LMWH, and warfarin is not the right agent for monitoring or continuation in early pregnancy.
15. A 32-year-old woman presents for follow-up 3 months after being diagnosed with a pulmonary embolism. The event occurred six weeks after she started taking a combined oral contraceptive pill. She has completed a 3-month course of apixaban and is asymptomatic. She has no family history of blood clots. Which of the following is the most accurate statement regarding testing for inherited thrombophilias?
    Answer: Testing is not indicated because the PE was provoked and the results will not alter management. This patient had a pulmonary embolism provoked by a major, modifiable risk factor (oral contraceptives). The standard treatment is a finite course (3 months) of anticoagulation. Testing for inherited thrombophilias is generally not recommended in this setting because the results would not change the management plan. The presence of a thrombophilia would not extend the duration of therapy for a clearly provoked event. Regardless of thrombophilia status, she will be advised to avoid estrogen-containing contraceptives in the future.
16. A 78-year-old man with a history of type 2 diabetes and hypertension is hospitalized for an acute pulmonary embolism. His baseline serum creatinine is 2.6 mg/dL, with an estimated GFR of 24 mL/min/1.73m². He is being transitioned from an intravenous heparin infusion to a long-term oral anticoagulant. Which of the following is the most appropriate choice for this patient?
    Answer: Warfarin with enoxaparin bridge. This patient has severe chronic kidney disease (CKD) with a GFR <30 mL/min. Most direct oral anticoagulants (DOACs) are renally cleared and are either contraindicated or require caution and have limited data in severe CKD. Rivaroxaban and dabigatran are contraindicated in the US for VTE treatment with a CrCl <30 mL/min. While apixaban can be used, its use is based on pharmacokinetic data rather than large trials in this population. Warfarin is not renally cleared and is the most studied and recommended oral anticoagulant for patients with severe CKD or end-stage renal disease. It should be initiated with a parenteral bridge (e.g., heparin or enoxaparin) until the INR is therapeutic.
17. A 66-year-old man on warfarin for a PE has an INR of 4.5 at a routine follow-up visit. He has no signs of active bleeding. He reports that he recently took a course of ciprofloxacin for a urinary tract infection. What is the most appropriate next step in management?
    Answer: Hold the warfarin dose for today and recheck the INR in 1-2 days. When managing warfarin overdose, your approach depends on the degree of INR elevation and presence of bleeding. This patient has a supratherapeutic INR (4.5) without active bleeding, likely due to ciprofloxacin inhibiting warfarin metabolism through CYP450 interactions. For INR levels between 4.5-10 without bleeding, the standard approach is to hold warfarin temporarily and monitor closely. The INR will naturally decrease as warfarin's effect wanes (warfarin has a half-life of 36-42 hours). This allows for safe correction without risking overcorrection that could lead to thrombotic complications. Choice D is correct because holding warfarin and rechecking INR in 1-2 days allows controlled monitoring of the INR decline while maintaining anticoagulation benefits as the ciprofloxacin effect diminishes. Choice A (oral vitamin K 2.5 mg) would be appropriate for INR >10 without bleeding, but risks overcorrection and warfarin resistance for several days. Choice B ignores the dangerous INR elevation - continuing warfarin could worsen the coagulopathy, and avoiding all antibiotics isn't realistic long-term management. Choice C (FFP transfusion) is reserved for life-threatening bleeding or emergency surgery needs, as it's expensive, carries transfusion risks, and provides only temporary reversal. Key strategy: Remember the INR thresholds for warfarin management: 3-5 without bleeding = hold doses and monitor; 5-9 without bleeding = hold and consider low-dose vitamin K; >9 or any bleeding = vitamin K; life-threatening bleeding = vitamin K plus FFP/PCC.
18. A 70-year-old woman taking apixaban 5 mg twice daily for a PE two months ago reports increased bruising and an episode of epistaxis that resolved with pressure. She is worried about these side effects. She is hemodynamically stable and her hemoglobin is at baseline. What is the most appropriate next step?
    Answer: Reassure the patient and continue the current therapy. Minor, or 'nuisance,' bleeding such as increased bruising and minor epistaxis is a common side effect of anticoagulation. In the absence of major or clinically significant bleeding, the best course of action is to reassure the patient that these effects are expected and that the benefit of preventing a recurrent PE outweighs the inconvenience of this minor bleeding. Andexanet alfa is for life-threatening bleeding. Reducing the dose would be inappropriate for VTE treatment and would undertreat the patient. Switching to warfarin is unlikely to reduce minor bleeding and is less convenient.
19. A 55-year-old woman with recurrent unprovoked PE (two episodes, last 14 months ago) presents for routine anticoagulation follow-up. Risk factors include prior estrogen-containing OCP use (stopped), obesity, and strong family history of VTE; she has no active cancer. She is on warfarin with target INR 2.0–3.0, monitored every 4 weeks; last two INRs were 2.4 and 2.6. She now reports 3 days of dark stools, lightheadedness on standing, and increased bruising; no chest pain or dyspnea. Vitals: BP 104/66, HR 102, SpO2 98% RA. Exam shows conjunctival pallor and ecchymoses. Labs today: INR 3.8, Hgb 8.7 g/dL (baseline 12.1), platelets 210k, BUN 34 mg/dL, creatinine 1.3 mg/dL (eGFR 52 mL/min/1.73 m²). She recently started ibuprofen for back pain. What is the most appropriate next step in management for this patient?
    Answer: Hold warfarin, administer reversal, and evaluate for gastrointestinal bleeding source urgently This question tests the understanding of pulmonary embolism management and anticoagulation follow-up in a clinical context relevant to USMLE Step 3. The principle focus is on applying clinical guidelines for anticoagulation management and recognizing complications arising from therapy. In this scenario, factors such as the patient's INR of 3.8, dark stools, lightheadedness, hemoglobin drop, and recent ibuprofen use are critical for decision-making. The correct answer addresses these factors by suggesting holding warfarin, administering reversal, and urgently evaluating for gastrointestinal bleeding, demonstrating the application of clinical guidelines for major bleeding events. A common distractor might suggest continuing warfarin and adding a proton pump inhibitor, which fails to consider the urgency of reversal and evaluation in active bleeding. To prepare for similar questions, students should focus on understanding anticoagulation management guidelines, recognize symptoms indicative of complications, and practice applying this knowledge to case scenarios.
20. A 62-year-old man with metastatic pancreatic cancer was diagnosed with a pulmonary embolism 2 months ago and started on warfarin. He presents today with a newly painful and swollen left leg. His INR today is 2.6. An ultrasound confirms an acute deep vein thrombosis. What is the most appropriate change in his anticoagulation therapy?
    Answer: Switch from warfarin to therapeutic-dose low-molecular-weight heparin. This patient has a recurrent venous thromboembolism (VTE) despite being on therapeutic warfarin, representing a treatment failure in the setting of cancer-associated thrombosis. The recommended treatment in this situation is to switch to long-term low-molecular-weight heparin (LMWH), such as enoxaparin, which has been shown to be more effective than vitamin K antagonists for cancer-associated VTE. Increasing the INR target has not been shown to be effective and increases bleeding risk. Adding an antiplatelet agent is not indicated for VTE treatment. An IVC filter is reserved for patients with contraindications to anticoagulation.

Start this quiz